ADC Therapeutics to Present at the Jefferies Healthcare Conference

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) announced that CEO Ameet Mallik will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 9:00 am ET. A live webcast of the presentation will be accessible on the company's Investors page, with a replay available for about 30 days. ADC Therapeutics focuses on targeted antibody drug conjugates for cancer treatment, including ZYNLONTA, approved for specific lymphoma types. The company is based in Lausanne, Switzerland, with additional operations in London, San Francisco Bay Area, and New Jersey.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 9:00 am ET.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005177/en/

Investors



Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

+44 7879 627205



Amanda Hamilton

ADC Therapeutics

amanda.hamilton@adctherapeutics.com

+1 917-288-7023



Media



Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

+1 914-552-4625

Source: ADC Therapeutics SA

FAQ

When is ADC Therapeutics participating in the Jefferies Healthcare Conference?

ADC Therapeutics will participate in the Jefferies Healthcare Conference on June 8, 2022, at 9:00 am ET.

How can I watch ADC Therapeutics' presentation at the Jefferies Healthcare Conference?

You can watch ADC Therapeutics' presentation via a live webcast on the Events & Presentations page of their Investors section.

What is ZYNLONTA's approval status?

ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for treating relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapy lines.

What is the focus of ADC Therapeutics?

ADC Therapeutics focuses on developing next-generation targeted antibody drug conjugates (ADCs) to improve cancer treatment.

Where is ADC Therapeutics headquartered?

ADC Therapeutics is headquartered in Lausanne, Switzerland.